Cancer treatment can lead to combined heart and kidney complications, which can have a significant impact on patient outcomes. Chemotherapy and radiation therapy used to treat cancer can cause damage to both the heart and kidneys, leading to a range of complications. Managing combined heart and kidney complications following cancer treatment requires a collaborative and multidisciplinary approach, with regular monitoring and personalized management plans tailored to the individual patient’s needs.
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system. Consequently, checkpoint inhibitors can cause autoimmune reactions, resulting in adverse effects. Prompt identification and management of adverse effects are critical for patients under checkpoint inhibitor therapy due to the potential severity and unpredictability of these immune-related adverse events.
Background: Desmopressin has a theoretical rationale to reduce procedural bleeding risk but results from randomized controlled trials are mixed. Methods: PubMed, EMBASE, and Google Scholar were searched on October 27, 2025 to identify studies evaluating Desmopressin administered prior to kidney biopsy. Risk of bias was assessed using the Cochrane Risk of Bias 2.0 tool. Statistical analysis was performed using RevMan software to calculate Odd’s Ratios and assess heterogeneity with the I 2 statistic. Publication bias was assessed with Egger’s test. A sensitivity analysis was performed due to heterogeneity via the leave-one-out method with revised estimated odds presented thereafter. Results: 17 studies including 5394 participants were analyzed. The pooled estimated odds ratio (OR) for total bleeding was 0.89 [0.59 - 1.36], p = 0.60, I 2 = 85%. In subgroup analysis the pooled estimated OR for subcutaneous administration was 0.37 [0.21 - 0.65], p < 0.001, I 2 = 0%); intravenous administration was 1.47 [1.05 - 2.05], p =0.03, I 2 = 61%; intranasal administration was 0.68 [0.30 - 1.56], p = 0.37, I 2 = 87%; and estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m 2 was 0.74 [0.40 - 1.37 p =0.34, I 2 = 81%. After sensitivity analysis the revised OR for intranasal administration was 0.42 [0.31 - 0.59], p <0.001 and for eGFR < 60 was 0.55 [0.38 - 0.81], p = 0.002. The pooled estimated OR for severe hyponatremia was 3.85 (95% CI [2.12 - 7.00], p <0.001, I 2 = 33%. Conclusions: Overall there was no reduction in odds of bleeding but with high between-group heterogeneity. There were lower odds of bleeding in the intranasal and subcutaneous administration subgroups. Desmopressin resulted in higher odds of hyponatremia.
12 November 2026 in Journal of the American Heart Association
Background: The 2026 American College of Cardiology/American Heart Association dyslipidemia guideline replaces the pooled cohort equations with the atherosclerotic cardiovascular disease component of the Predicting Risk of Cardiovascular Disease Events equations for primary prevention risk estimation and modifies lipid‐lowering therapy (LLT) eligibility by lowering the risk‐based treatment threshold and expanding diabetes and chronic kidney disease criteria. The population‐level impact of this transition is uncertain. Methods: We analyzed National Health and Nutrition Examination Survey 2021 to 2023 participants aged 40 to 75 years without self‐reported atherosclerotic cardiovascular disease and with available low‐density lipoprotein cholesterol. Survey weights were used to generate national estimates. Guideline‐supported LLT eligibility was assessed under the 2018 pooled cohort equations–based American College of Cardiology/American Heart Association cholesterol framework and the 2026 Predicting Risk of Cardiovascular Disease Events–based American College of Cardiology/American Heart Association dyslipidemia framework. Current LLT use was assessed among guideline‐supported adults. Results: The analytic sample included 1662 participants, representing 115.05 million US adults. LLT was supported for 42.82 million adults under the 2018 framework and 42.17 million under the 2026 framework, a net decrease of 0.65 million. Reclassification was substantial: 37.42 million remained supported, 5.40 million lost support, 4.75 million newly gained support, and 67.48 million remained unsupported. Among supported adults, current LLT use was 39.4% under the 2018 framework and 40.5% under the 2026 framework. Conclusions: Transition to the 2026 Predicting Risk of Cardiovascular Disease Events–based framework produced little net change in LLT eligibility but meaningfully changed who was supported for therapy. Persistent undertreatment remains a major implementation gap.
23 September 2023 in Journal of Preventive Epidemiology
Collapsing glomerulopathy is a rare and serious disease that is characterized by a rapid deterioration of kidney function and heavy proteinuria. This disease is a variant of focal segmental glomerulosclerosis (FSGS). The disease is more serious than other types of FSGS, with high risks of renal failure and poor prognosis. Collapsing glomerulopathy is often resistant to immunosuppressive therapy and can rapidly result in renal failure, making diagnosing and managing this disease an enormous challenge.
23 September 2023 in Journal of Parathyroid Disease
Prospects in parathyroid diseases involve a multidisciplinary approach that combines research, clinical practice, and patient-centered care to improve understanding, diagnosis, and treatment outcomes for individuals with these conditions. Accordingly, further advancements in genetics, biomarkers, imaging, targeted therapies, non-surgical treatments, and personalized medicine can potentially revolutionize diagnosing, treating, and managing parathyroid diseases.